Impact of anatomic site on antigen-presenting cells in cancer
<jats:p>Checkpoint blockade immunotherapy (CBT) can induce long-term clinical benefits in patients with advanced cancer; however, response rates to CBT vary by cancer type. Cancers of the skin, lung, and kidney are largely responsive to CBT, while cancers of the pancreas, ovary, breast, and me...
| Main Authors: | , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | English |
| Published: |
BMJ
2023
|
| Online Access: | https://hdl.handle.net/1721.1/146984 |
| _version_ | 1826202972731736064 |
|---|---|
| author | Zagorulya, Maria Duong, Ellen Spranger, Stefani |
| author2 | Massachusetts Institute of Technology. Department of Biology |
| author_facet | Massachusetts Institute of Technology. Department of Biology Zagorulya, Maria Duong, Ellen Spranger, Stefani |
| author_sort | Zagorulya, Maria |
| collection | MIT |
| description | <jats:p>Checkpoint blockade immunotherapy (CBT) can induce long-term clinical benefits in patients with advanced cancer; however, response rates to CBT vary by cancer type. Cancers of the skin, lung, and kidney are largely responsive to CBT, while cancers of the pancreas, ovary, breast, and metastatic lesions to the liver respond poorly. The impact of tissue-resident immune cells on antitumor immunity is an emerging area of investigation. Recent evidence indicates that antitumor immune responses and efficacy of CBT depend on the tissue site of the tumor lesion. As myeloid cells are predominantly tissue-resident and can shape tumor-reactive T cell responses, it is conceivable that tissue-specific differences in their function underlie the tissue-site-dependent variability in CBT responses. Understanding the roles of tissue-specific myeloid cells in antitumor immunity can open new avenues for treatment design. In this review, we discuss the roles of tissue-specific antigen-presenting cells (APCs) in governing antitumor immune responses, with a particular focus on the contributions of tissue-specific dendritic cells. Using the framework of the Cancer-Immunity Cycle, we examine the contributions of tissue-specific APC in CBT-sensitive and CBT-resistant carcinomas, highlight how these cells can be therapeutically modulated, and identify gaps in knowledge that remain to be addressed.</jats:p> |
| first_indexed | 2024-09-23T12:29:01Z |
| format | Article |
| id | mit-1721.1/146984 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T12:29:01Z |
| publishDate | 2023 |
| publisher | BMJ |
| record_format | dspace |
| spelling | mit-1721.1/1469842023-01-06T03:26:21Z Impact of anatomic site on antigen-presenting cells in cancer Zagorulya, Maria Duong, Ellen Spranger, Stefani Massachusetts Institute of Technology. Department of Biology <jats:p>Checkpoint blockade immunotherapy (CBT) can induce long-term clinical benefits in patients with advanced cancer; however, response rates to CBT vary by cancer type. Cancers of the skin, lung, and kidney are largely responsive to CBT, while cancers of the pancreas, ovary, breast, and metastatic lesions to the liver respond poorly. The impact of tissue-resident immune cells on antitumor immunity is an emerging area of investigation. Recent evidence indicates that antitumor immune responses and efficacy of CBT depend on the tissue site of the tumor lesion. As myeloid cells are predominantly tissue-resident and can shape tumor-reactive T cell responses, it is conceivable that tissue-specific differences in their function underlie the tissue-site-dependent variability in CBT responses. Understanding the roles of tissue-specific myeloid cells in antitumor immunity can open new avenues for treatment design. In this review, we discuss the roles of tissue-specific antigen-presenting cells (APCs) in governing antitumor immune responses, with a particular focus on the contributions of tissue-specific dendritic cells. Using the framework of the Cancer-Immunity Cycle, we examine the contributions of tissue-specific APC in CBT-sensitive and CBT-resistant carcinomas, highlight how these cells can be therapeutically modulated, and identify gaps in knowledge that remain to be addressed.</jats:p> 2023-01-05T18:53:37Z 2023-01-05T18:53:37Z 2020 2023-01-05T18:46:04Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/146984 Zagorulya, Maria, Duong, Ellen and Spranger, Stefani. 2020. "Impact of anatomic site on antigen-presenting cells in cancer." Journal for ImmunoTherapy of Cancer, 8 (2). en 10.1136/JITC-2020-001204 Journal for ImmunoTherapy of Cancer Creative Commons Attribution NonCommercial License 4.0 https://creativecommons.org/licenses/by-nc/4.0/ application/pdf BMJ BMJ |
| spellingShingle | Zagorulya, Maria Duong, Ellen Spranger, Stefani Impact of anatomic site on antigen-presenting cells in cancer |
| title | Impact of anatomic site on antigen-presenting cells in cancer |
| title_full | Impact of anatomic site on antigen-presenting cells in cancer |
| title_fullStr | Impact of anatomic site on antigen-presenting cells in cancer |
| title_full_unstemmed | Impact of anatomic site on antigen-presenting cells in cancer |
| title_short | Impact of anatomic site on antigen-presenting cells in cancer |
| title_sort | impact of anatomic site on antigen presenting cells in cancer |
| url | https://hdl.handle.net/1721.1/146984 |
| work_keys_str_mv | AT zagorulyamaria impactofanatomicsiteonantigenpresentingcellsincancer AT duongellen impactofanatomicsiteonantigenpresentingcellsincancer AT sprangerstefani impactofanatomicsiteonantigenpresentingcellsincancer |